Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 6,675 |
|
|||||
| News | - |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NVS | NYSE | Depository Receipt |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.39 | 0.42% | 92.96 | 07:36:29 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 92.57 |
| Trades | Volume | Avg Volume |
|---|---|---|
| 41 | 6,675 | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:34:22 | 95 | 93.00 | USD |
Novartis (NVS) Options Flow Summary
Novartis AG Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 184.45B | 2.04B | - | 54.11B | 14.85B | 7.27 | 12.42 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Novartis
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
NVS Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. |
